A convincing hit puts approval, and potentially partnerships, on the table.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
Despite assurances by Esperion, Daiichi is refusing to pay up after the Clear Outcomes disappointment.